| 2.03 0.08 (4.1%) | 05-01 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term | |
|||
| Targets | 6-month : | 2.42 |
1-year : | 2.83 |
| Resists | First : | 2.07 |
Second : | 2.42 |
| Pivot price | 1.96 |
|||
| Supports | First : | 1.81 |
Second : | 1.64 |
| MAs | MA(5) : | 1.94 |
MA(20) : | 1.89 |
| MA(100) : | 1.85 |
MA(250) : | 2  |
|
| MACD | MACD : | 0 |
Signal : | 0 |
| %K %D | K(14,3) : | 70 |
D(3) : | 67.4 |
| RSI | RSI(14): 63.5 |
|||
| 52-week | High : | 2.41 | Low : | 1.64 |
Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and NEUTRAL in mid-long term.[ SEER ] has closed below upper band by 12.3%. Bollinger Bands are 38.8% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 2.08 - 2.09 | 2.09 - 2.1 |
| Low: | 1.89 - 1.9 | 1.9 - 1.91 |
| Close: | 2.01 - 2.03 | 2.03 - 2.05 |
Seer, Inc., a life sciences company, engages in developing and commercializing products to decode the secrets of the proteome. It develops Proteograph Product Suite, an integrated solution that comprises consumables, an automation instrumentation, and software that allows researchers to conduct proteomic studies in therapeutic and diagnostic research, and clinical trials. The company intends to sell its products for research purposes, which cover academic institutions, life sciences, and research laboratories, as well as biopharmaceutical and biotechnology companies for non-diagnostic and non-clinical purposes. It has a collaboration agreement with Discovery Life Sciences, LLC. and the Salk Institute for Biological Studies. The company was formerly known as Seer Biosciences, Inc. and changed its name to Seer, Inc. in July 2018. Seer, Inc. was incorporated in 2017 and is headquartered in Redwood City, California.
Thu, 30 Apr 2026
Board pay and severance terms detailed in Seer (NASDAQ: SEER) filing - Stock Titan
Wed, 29 Apr 2026
Seer to Report First Quarter 2026 Financial Results on May 13, 2026 - Investing News Network
Wed, 29 Apr 2026
The Radoff-JEC Group Responds to Seer, Inc.?s Rejection of Acquisition Proposal - marketscreener.com
Wed, 29 Apr 2026
Seer (SEER) Shareholders Challenge Board's Rejection of Acquisition Proposal - GuruFocus
Wed, 29 Apr 2026
The Radoff-JEC Group Responds to Seer, Inc.'s Rejection of April 24th Acquisition Proposal - Investing News Network
Mon, 27 Apr 2026
Seer (NASDAQ: SEER) Board Rejects Radoff-JEC’s $2.35 Cash+CVR Offer - Stock Titan
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Outperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 56 (M) |
| Shares Float | 38 (M) |
| Held by Insiders | 9.7 (%) |
| Held by Institutions | 55.3 (%) |
| Shares Short | 733 (K) |
| Shares Short P.Month | 905 (K) |
| EPS | -1.28 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 4.61 |
| Profit Margin | 0 % |
| Operating Margin | -413.9 % |
| Return on Assets (ttm) | -14.8 % |
| Return on Equity (ttm) | -25.1 % |
| Qtrly Rev. Growth | 5 % |
| Gross Profit (p.s.) | 0.14 |
| Sales Per Share | 0.29 |
| EBITDA (p.s.) | -1.28 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -44 (M) |
| Levered Free Cash Flow | -28 (M) |
| PE Ratio | -1.59 |
| PEG Ratio | 0 |
| Price to Book value | 0.44 |
| Price to Sales | 6.9 |
| Price to Cash Flow | -2.58 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|